Pharsight

Minivelle patents expiration

MINIVELLE's oppositions filed in EPO
MINIVELLE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5656286 NOVEN Solubility parameter based drug delivery system and method for altering drug saturation concentration
Aug, 2014

(9 years ago)

US9724310 NOVEN Transdermal estrogen device and delivery
Jul, 2028

(4 years from now)

US8231906 NOVEN Transdermal estrogen device and delivery
Jul, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6024976 NOVEN Solubility parameter based drug delivery system and method for altering drug saturation concentration
Jan, 2014

(10 years ago)

US5646286 NOVEN Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines
Aug, 2014

(9 years ago)

US6841716 NOVEN Patch
Apr, 2020

(4 years ago)

US9833419 NOVEN Transdermal estrogen device and delivery
Jul, 2028

(4 years from now)

US9730900 NOVEN Transdermal estrogen device and delivery
Jul, 2028

(4 years from now)

Minivelle is owned by Noven.

Minivelle contains Estradiol.

Minivelle has a total of 8 drug patents out of which 4 drug patents have expired.

Expired drug patents of Minivelle are:

  • US6024976
  • US5646286
  • US6841716
  • US5656286

Minivelle was authorised for market use on 23 September, 2014.

Minivelle is available in film, extended release;transdermal dosage forms.

Minivelle can be used as a method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent no. 9730900.

The generics of Minivelle are possible to be released after 04 July, 2030.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 23 September, 2014

Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent ...

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of MINIVELLE before it's drug patent expiration?
More Information on Dosage

MINIVELLE family patents

Family Patents